Home / Home

Kidney Cancer Research

Kidney cancer research includes IO/targeted combinations, adjuvant strategies, and risk-adapted approaches in clear-cell and non-clear-cell RCC.

Our Kidney Cancer Analysis

  • August 19, 2026Clinical Cancer ResearchHCRN GU16-260 (NCT03117309)

    Tumor Immune Cell Biomarkers Predict Response to First-Line Nivolumab in Kidney Cancer

    In a correlative biomarker analysis of the HCRN GU16-260 trial, non-exhausted CD8+ T cells were linked to higher response rates and longer progression-free survival in treatment-naive metastatic clear-cell RCC treated with first-line nivolumab.

Related topics: Immunotherapy Response Biomarkers